University of Texas at El Paso

DigitalCommons@UTEP
Open Access Theses & Dissertations

2015-01-01

The Role of p62/IMP2 in Breast Cancer
Progression
Yang Li
University of Texas at El Paso, nellyranran@hotmail.com

Follow this and additional works at: https://digitalcommons.utep.edu/open_etd
Part of the Biology Commons
Recommended Citation
Li, Yang, "The Role of p62/IMP2 in Breast Cancer Progression" (2015). Open Access Theses & Dissertations. 1088.
https://digitalcommons.utep.edu/open_etd/1088

This is brought to you for free and open access by DigitalCommons@UTEP. It has been accepted for inclusion in Open Access Theses & Dissertations
by an authorized administrator of DigitalCommons@UTEP. For more information, please contact lweber@utep.edu.

THE ROLE OF p62/IMP2 IN BREAST CANCER PROGRESSION

Yang Li
Department of Biological Sciences

Approved by:

____________________________
Jianying Zhang, M.D, Ph.D., Chair
____________________________
Giulio Francia, Ph.D., Co-Chair
____________________________
Marc B. Cox, Ph.D
____________________________
Jianjun Sun, Ph.D
____________________________
Wei Qian, Ph.D

Charles Ambler, Ph.D.
Dean of the Graduate School

Copyright ©

by
Yang Li
2015

THE ROLE OF p62/IMP2 IN BREAST CANCER PROGRESSION

by

Yang Li, M.S.

DISSERTATION

Presented to the Faculty of the Graduate School of
The University of Texas at El Paso
in Partial Fulfillment
of the Requirements
for the Degree of

DOCTOR OF PHILOSOPHY

Department of Biological Sciences
THE UNIVERSITY OF TEXAS AT EL PASO
May 2015

Acknowledgements
This dissertation was completed under the supervision and guidance of my supervisor Dr.
Jianying Zhang, and my co-mentor Dr. Giulio Francia. I am truly thankful to these two
supervisors. They have given me the best support any student can ask for and trained me to
become a competent Ph.D. student. Dr. Jianying Zhang, thank you again for providing me such a
great opportunity to work in your lab. I had such a great time to work with you. Your vision,
suggestion and wonderful questions are and will be always inspiring to my research and my
future career. Dr. Francia, your encouragement strengthened me all the time whenever I had
difficulties in pursuing my Ph.D. degree.
I would also like to thank each member of my dissertation committee, Dr. Marc B. Cox,
Dr. Jianjun Sun and Dr. Wei Qian. They help me all the time with my research project. Thanks
for advising and support.
I would also like to extend my thanks to all members in Dr. Zhang’s lab and Dr.
Francia’s lab, over the past four years. Dr. Liping Dai, Dr. Bo Peng, , Dr. Ningjing Lei, Dr.
Pengfei Ren, Dr. Yurong Chai, Dr. Yahara, Ms. Xinxin Liu, Mr. Jitian Li, , Mr. Hongfei Zhang,
Mr. Jianxiang Shi, Ms. Paloma Valenzuela, Ms. Karla Parra, Mr. Irving Miramontes. Thank you
for your friendship and support.
At last, I would like to thank my parents, my husband and my son. They supported me
emotionally, spiritually, financially without any reservation. Their great support helped me to
overcome many difficulties in my life. I am very grateful to them.

iv

Abstract
Breast cancer is one of the most common types of cancer in women. In most patients with
breast cancer, it is not the primary tumor that leads to death, but rather metastatic tumors. Once
breast cancer spreads to other organs in the body, the disease becomes almost incurable. It is
estimated that about 20% to 50% of patients diagnosed with primary breast cancer will develop
metastatic disease. Considering this, it is important to understand the molecular and cellular
mechanisms behind metastatic breast cancer and to identify new proteins that regulate the
metastatic process. These proteins may be used as targets for possible therapeutic intervention.
This study focuses on one such protein: p62/IMP2. We found that p62/IMP2, a member of IGF2
mRNA-binding protein (IMP) family, may play an important role in breast cancer metastasis.
In our study, the clinical data demonstrated that p62/IMP2 is highly associated with
breast cancer. The overexpression of p62/IMP2 can be observed in breast cancer tissues, and a
high frequency of its autoantibody can be detected in sera from patients with breast cancer. In
our in vitro study, we found that overexpression of p62/IMP2 in breast cancer cell may promote
breast cancer metastasis by increasing cell migration and reducing cell adhesion. In the study
with the RT Profiler qPCR Array, we noticed that most changed genes with the overexpression of
p62/IMP2 play important roles relating to cancer metastasis, such as cell migration and cell
adhesion. Among the changed genes, CTGF was first identified as a novel target of p62/IMP2. In
summary, p62/IMP2 may be an important regulator in breast cancer metastasis by controlling a
group of adhesive molecules.
In future studies, we will focus on two points. 1) To confirm the results from in vitro
study by using the in vivo experiments. In the in vivo study, we will investigate if p62/IMP2
really promotes breast cancer metastasis. 2) CTGF and p62/IMP2 expression in the breast cancer
v

cells will be detected and the staining of CTGF and p62/IMP2 will be performed in tumor
tissues. The completion of this project is expected to expand our knowledge regarding the
function of p62/IMP2 in breast cancer metastasis and further improve our understanding of the
molecular process in the transition from primary breast cancer to metastatic breast cancer.
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Chapter 1: Introduction
1.1 Human breast cancer
Breast cancer is a type of cancer that develops from breast tissue and cells. There are
more than 18 subtypes of breast cancer and they vary based on the site of tumor’s origin and
whether the tumor is in situ or invasive, or in the reproductive status [1]. The most common type
of breast cancer is ductal carcinomas, which develops from the lactiferous duct (milk duct).
Another common type is lobular carcinomas, a cancer that begins in the lobules. Based on a
number of biological markers (proteins found in cells that have been associated with mechanisms
tied to breast cancer), a newer set of breast cancer classifications has been established: basal,
HER-2 over-expression, luminal A, luminal B, and unclassified [2]. These new classifications
offer a better understanding the mechanisms behind breast cancer and provide newer therapeutic
targets.
As research advanced and developments in diagnosis and therapeutic strategies developed,
female breast cancer rates have gradually decreased since 2000. However, breast cancer is still
one of the major causes of cancer-related death for women throughout the world. It is estimated
that one in eight women born today will be diagnosed with breast cancer during their life.
The etiology of breast cancer is far from well-known. It is generally believed that both the
combination of environmental factors and genetic predisposition contribute to the development
of this disease. The environmental factors include obesity, alcohol consumption, estrogen
exposure, radiation exposure, and aging [3, 4]. However, how these environmental factors
increase the risk for breast cancer is still largely unknown. A genetic pre-disposition to breast
cancer is estimated to cause only about 5%-10% of breast cancer cases. These well-known
mutations include BRCA1, BRCA2, p53, PTEN, STK11, CHEK2, ATM, BRIP1, and PALB2
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[5]. Among them, the mutations in the BRCA1 or BRCA2 tumor suppressor genes are the most
important contributors to hereditary breast cancer. The BRCA1 and BRCA2 proteins are
involved in various cellular processes. It has been demonstrated that BRCA1 and BRCA2
regulate some genes involved in DNA repair, the cell cycle, and apoptosis [6]. If the genes are
mutated, the mutated BRCA1 and BRCA2 cannot properly repair damaged DNA, which
increases the risk of breast cancer. However, there is still much to figure out in understanding the
mechanisms, preventions and possible therapeutics for breast cancer.
1.2 Breast cancer metastasis
The major cause of the death in breast cancer is not caused by the primary tumor but rather
by the metastatic disease. It is estimated that about 20% to 50% of patients diagnosed with
primary breast cancer will develop metastatic disease [7]. Once breast cancer spreads to other
parts of the body, the disease becomes almost incurable [8]. Therefore, breast cancer metastasis
is a significant challenge that cancer researchers face [7]. To overcome this challenge, we must
understand how breast cancer metastasis happens and how the mechanisms behind it operate.
Breast cancer metastasis is just like other cancer metastasis in the sense that the process
consists of a series of successive steps. The invasion-metastasis cascade (Fig.1.) starts with the
primary tumor invasion into adjacent normal tissues such as the stroma [9]. Cancer cells from
the primary site then breach the basement membrane and penetrate the blood vessels, which
releases them into the bloodstream. Within the circulatory system, cancer cells interact with
other blood cells such as platelets to form cell lumps. These lumps can become stuck in blood
capillaries when they travel through the body. After being trapped, cancer cells will
subsequently extravasate and settle down in distant organs [10]. Then the secondary tumor
deposits occur and the same process may be repeated, sometimes more rapidly.
2

Figure 1: The invasion-metastasis cascade. Cancer cells grow in the primary site, then
invade the local tissues and eventually go into the circulation. These cancer cells travel to the
distant parts of our body, and settle down and grow at the secondary sites.
In terms of breast cancer in humans, the common sites of metastasis include bones, liver, lungs,
and the brain [11]. Furthermore, cancer metastasis involves not only migration of cancer cells but
also interaction between cancer cells and their surrounding cells. Cancer cells will induce
fibroblast nearby to secrete stromelysin-3, which can break down the basement membrane.
Cancer cells also induce macrophages surrounding them and secrete EGF to support them [12].

1.2.1 The role of epithelial-mesenchymal transition in breast cancer metastasis
Epithelial-mesenchymal transition (EMT) is a process through which epithelial cells lose
the adherent tight junctions that keep them in contact with their neighbors and gain migratory
properties to become mesenchymal cells (Table 1) [13]. Cancer cells at the edge of a primary
3

tumor undergo an EMT as they invade into the stroma and migrate to blood vessels. They must
shed many of their epithelial phenotypes and detach from epithelial sheets to become
mesenchymal. EMT causes cancer cells to invade locally, intravasate, and subsequently
extravasate into a distant tissue. Once cancer cells grow in distant sites, these cells will regain an
epithelial phenotype via a mesenchymal-epithelial transition (MET) [14].
Table 1: Changes associated with the epithelial-mesenchymal transition

Epithelial-mesenchymal transition is often induced by stromal signals. Loss of E-cadherin is
considered to be a fundamental event in EMT. Many signaling pathways (TGFbeta, FGF, EGF, HGF, Wnt/beta-catenin and Notch) and hypoxia may induce EMT. Wnt/betacatenin signaling pathway is very important to breast cancer metastasis. Active Wnt/beta-catenin
pathway correlates with poor prognosis in breast cancer patients. Wnt in breast cancer cells can
induce the EMT regulator SNAIL and upregulates the mesenchymal marker, vimentin [13].
Consistently,SNAIL is highly expressed in both epithelial and endothelial cells of invasive breast
cancer but not observed in normal breast cancer. Transforming growth factor-β (TGF-β)
signaling is implicated as the critical promoter of EMT. The activated TGF-beta/Smad signaling
can contribute the form of the breast cancer bone metastasis [15].

1.2.2 The role of cell adhesion in breast cancer metastasis
It has been demonstrated that the alternation of cell adhesion is very critical in the
4

metastasis process of (breast) cancer. The invasive tumor cells must experience the change of
cell to cell adhesion and cell-matrix adhesion [16, 17].
The most important ‘cell to cell adhesion’ is the loss of E-cadherin and the gain of Ncadherin in the EMT process. The shutdown of E-cadherin enables breast cancer cells to break
away from the neighbor cells, and the high level expression of N-cadherin allows breast cancer
cells to obtain contact with various types of mesenchymal cells, such as fibroblasts and
endothelial cells that reside in the stroma. In this way, breast cancer cells disseminate from the
primary tumor and obtain invasive capabilities for metastasis. Therefore the process of
metastasis is also known as a cadherin switch.
The adhesion of breast cancer cells to the ECM (cell-matrix adhesion) can be mediated
through integrins. Integrins are transmembrane receptors and they can bind to the components in
extracellular matrix including fibronectin, vitronectin, laminin or collagen. Integrins can affect
cellular shapes and their movement by controlling bidirectional signaling (inside-out signaling
and the out-inside signaling). Activated integrins can also recruit proteases such as
metalloproteinases (MMP) to the invading edge of a tumor and this can promote ECM
degradation for easy spread of cancer cells.
Similarly, cell adhesion is necessary for tumor cells in circulation to interact with platelets
and leukocytes to form new lumps for extravasation [18]. Let us take the immunoglobulin gene
superfamily (IgSF) as an example. IgSF is a large group of cell surface and soluble proteins, and
many members in this family are associated with metastasis in various cancers, including breast
cancer. It is reported that IgSF is implicated in cancer spread by regulating the adhesion between
circulating tumor cells and capillary endothelium or immunocytes [19].
Therefore, we can conclude that the deregulation of cell adhesion can be found in the
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whole process of cancer metastasis and many adhesive molecules are found to be involved in it.
1.3 The microenvironment of breast cancer metastasis: Extracellular matrix
A successful metastasis requires a local microenvironment or niches to support cancer cells
to survive, colonize and expand [20]. The major component of the niche is the extracellular
matrix (ECM). The increased or reduced adhesion between cancer cells and extracellular matrix
is in fact a result of the talking of cancer cells and ECM (a local microenvironment). The major
contribution of this talking is to promote cancer metastasis, although there is evidence that
talking also supports the growth of cells [16].
First, the angiogenesis in tumors depends on the stimulation of adhesion molecules. To
keep growth and increase in size, cancer cells must consume more oxygen and nutrients and
remove waste products at the same time. The formation of new blood vessels can supply more
energy for cell growth [21]. More importantly, these blood vessels also serve as a way for
systemic metastasis. It has been reported that soluble members of adhesion molecules are able to
stimulate angiogenesis. Secondly, it is generally believed that cancer stem cells possess
characteristics of both stem cells and cancer cells and hold the metastatic potential. Some
evidence suggests that ECM is a key component of the cancer stem cell niche necessary for cells
to acquire or maintain stem cell properties [22]. Consider how tenascin C, one of the ECM
components, can modulate FGF2 signaling which is essential for neural stem cell biology. On the
other hand, the loss of ECM contact reduces the number of stem cells.
In breast tissue, proteins of ECM not only work as a structural scaffold to maintain tissue
integrity but also determine cell fate. ECM provides an adhesive surface for cells to bind growth
factors and cytokine. The molecular signaling can be passed between cell and ECM in this way
[23]. In breast cancer an increase in the deposition of fibrotic stomal matrix such as collagen,
6

elastin, vitronectin, and matricellular proteins can be observed. The important ECM components
in breast cancer progression include hyluronan, matrix metalloproteinases, tenascin, and
thrombospondin. Hyaluronan (HA) is a highly abundant oligosaccharide and forms a significant
part of ECM. Hyaluronan is produced by Hyaluronan synthase (HAS). HAS can participate in all
of the stages of cancer metastasis. By producing anti-adhesive HA, HAS allows tumor cells to
release from the primary tumor mass. In animal models, expression of HAS is reported to
support mammary tumor invasion and metastasis [24]. In contrast, the inhibition of HAS leads to
reduced cancer progression.
Matrix metalloproteinsases is a sort of ECM modifying enzymes related with metastatic
breast cancer. The overexpression of MMPs is helpful to break basement membrane partially by
degrading collagen [25]. Tenascin is a member in the matricellular family and forms a critical
constituent of provisional matrix of wounds. In breast cancer it is highly up-regulated. Tenascin
C can also modulate FGF2 signaling, which is critical for neural stem cell biology. THBS1 is a
component of platelets, and this protein has double roles in cancer progression. On one hand,
THBS1 has been shown to represses growth of primary tumors. On the other hand, THBS1 is an
effective inducer of metastasis [26]. It is known that THBS1 is able to promote lung metastasis
and breast cancer metastasis, and its expression is associated with poor metastasis free survival
[27]. In conclusion, breast cancer metastasis results from interaction of cancer cells and the
microenvironment.
1.4 IGF2 mRNA binding proteins family
The family of insulin-like growth factor 2 mRNA binding proteins (IMP family) was first
identified as a family of fetal RNA-binding proteins that exhibits high affinity to the IGF2 in
1999 [28]. This family has three members: IMP1 (63KD), p62/IMP2 (66KD), and IMP3 (64KD).
7

The expression of IMP family is biphasic, with an early expression in the oocyte and in the
zygote, followed by a sharp peak in the expression from embryonic day 10.5 to 12.5 before a
decline towards the birth of a mouse [29]. Compared with the high expression in the embryo, the
expression of IMP family members is almost turned off in adult organs, except in reproductive
tissues. However, in various tumors the overexpression of IMPs is induced. Therefore IMPs are
viewed as oncofetal proteins [30].
Three members in the IMP family share similar protein structures in mammals. The sequence
identity between them ranges from 60% to 70% and the similarity ranges from 80% to 85%. All

Figure 2: The comparison of three members’ structure in IMPs. This figure showed that
the similarity between p62/IMP2 and related RRM-KH proteins IMP1 and IMP3.
members have six characteristic RNA-binding domains, including two N-terminal RNA
recognition motifs (RRMs) and four C-terminal heterogeneous nuclear ribonucleoprotein
(hnRNP) K-homology (KH) domains (Fig.2.). The structure similarity further explains why these
proteins share similar biological functions. As to the RRM domains, they are responsible for
protein-protein interaction, protein dimerization, and the stabilization of IMPs-RNA complexes.
As for KH domains, they are related with RNA-binding, granular RNP assembly, and RNA
8

localization [31, 29, 32, 33]. All three members are mainly cytoplasmic. In the cytoplasm, they
form large RNP granules dispersed in the whole cytoplasm, around the nucleus, or in cellular
protrusions. Additionally, they also have two nuclear export signals, which imply that they bind
to their target mRNAs in the nucleus and export their target mRNAs from the nucleus to the
cytoplasm [29].
Although IMPs are named as IGF2 mRNA-binding proteins, it has been known that they
can bind to many different target transcripts in different cellular contexts, and most of targets are
highly associated with tumor progression such as c-myc [34], beta-actin [35, 36], H19 [37],
CD44 [38], MDR1 [39], RAS [40, 41] and many others (Table 2). Therefore IMPs are
considered as valuable targets for cancer treatment. Within the IMP family, IMP1 (also named
IGF2BP1, CRD-BP, VICKZ1, ZBP-1) has been extensively investigated. IMP1 can direct the
localization of beta-actin mRNA to the leading edge of fibroblasts and increase cell motility in
cancer cells [31, 42]. The IMP1 gene is amplified in breast cancer and its expression has been
significantly associated with the absence of estrogen receptors [43]. Tissue specific induced
expression of IMP1 in transgenic mice promotes tumor formation [44]. Recent work on IMP1
protein structure has paved the way towards future drug design, possibly through fragment-based
screening or virtual ligand screening to inhibit binding of substrates such as the MYC or IGF2
mRNAs [45, 46]. p62/IMP2 has been extensively validated as a potential biomarker for early
cancers diagnosis [47, 48]. IMP3 is reported to be related with tumor aggressiveness and its
expression is a good predictor of prognosis in individual patients.

9

Table 2: Most important targets of IMPs

1.5 IMP2 gene, IMP2 protein and the regulation of IMP2
It is known that three isoforms of IMP2 are expressed in cancer cell lines. The longest
one is IMP2 with 66KD [28]. p62 (Acc. No.: NM001007225.1) is an isoform that extron 10 is
truncated from the IMP2 gene, which leads to 43 amino acids being omitted between KH2
domain and KH3 domain [49]. The shortest isoform is p58, resulting from leaky scanning of
IMP2 [50]. p58 lacks the first RRM domain in the N-terminal, so the binding affinity and
specificity to target mRNAs and protein partners is affected [51].
The IMP2 gene is located on 3q27.2. It is encoded by 16 extrons and 15 introns [29].
There is an AT-rich regulatory region in the first intron; HMGA2 can bind with this AT-rich
region to regulate IMP2 [52]. Interestingly, HMGA2 was also an oncofetal protein [53] so it has
a similar expression pattern to p62/IMP2. More importantly, HMGA2 is has recently been
reported to be a driver in cancer metastasis by inducing the epithelial-mesenchynal transition
(EMT) [54]. Therefore p62/IMP2 also has a potential role in promoting cancer metastasis as an
important target of HMGA2. The second intron of IMP2 gene is the largest intron by far, in
which a single nucleotide polymorphism is reported to be associated with type 2 diabetes [55,
56]. p62/IMP2 can bind different mRNAs to direct the fate of cells, and the binding is controlled
by its phosphorylation [55, 56]. It has been suggested that two serine sites (Ser162/Ser164) in the
10

N-terminal linker region of p62/IMP2 (between RRM2 domain and KH1 domain) can be
phosphorylated by mTOR, which will promote the binding with IGF2 and increase IGF2 protein
synthesis [57].
1.6 p62/IMP2 and cancer

1.6.1 p62/IMP2 is a tumor-associated antigen and its autoantibody is viewed as a potential
biomarker in early detection of cancer
Tumor-associated antigens (TAAs) are antigens that are highly correlated with tumor
cells. Many tumor cells produce tumor-associated antigens, which may be released in the
bloodstream or remain on the cell surface. TAAs have been identified in most of human cancers
including prostate cancer, malignant melanoma, and breast carcinoma [58]. The origin for TAAs
may be mutated proteins in cancer or abnormally high level of proteins in cancer that have a low
expression in normal cells [59]. These TAAs can be sensed by the human immune system as
foreign antigens and stimulate the immune system to produce the corresponding autoantibody.
Because these autoantibodies are stable in patients’ sera and easily detectable by ELISA [60],
they are viewed as a sort of biomarker in the early detection of cancer.
p62/IMP2 was first identified as a tumor-associated antigen known as p62 in
hephatocellular carcinoma by immunoscreening cDNA library from sera of patients with liver
cancer. This cytoplasmic protein p62 is an mRNA binding protein and belong to IMP family
binding to insulin-like growth factor 2 mRNA. The frequency of the autoantibody against
p62/IMP2 in sera from cancer patients is significantly higher than it in sera from healthy
individuals. The detectable antibody was present in 21.1% of patients with HCC from China but
not in the precursor diseases of HCC. In a study involving ovarian cancer, the frequency of
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autoantibody to p62/IMP2 was 29.4% in patients and 1.1% in healthy individuals [61]. Of 83
patients with digestive canal tumors, 32 showed the positive serum autoantibody to p62 (38.55%)
and 28 had metastasized (33.7 %) [62]. In prostate cancer, the prevalence of serum autoantibody
to p62/IMP2 was 25.2% in patients [63]. In esophageal cancer, the autoantibody of p62/IMP2
was detected in 16.8% of 119 esophageal cancer patients. In addition, a relatively higher
frequency of autoantibody response to IMP2/p62 was observed in patients with colon cancer
(23.4%, 15/64) compared to patients with colonic adenomas (4.8%, 2/42) and normal individuals
(2.9%, 1/34) [64]. This data suggested that p62/IMP2 and its autoantibody are closely associated
with cancer development. More importantly, the significant rise of autoantibody of p62/IMP2 is
also corresponding with the occurrence of cancers. As illustrated in Figure 3, four serum samples

Figure 3: The appearance of autoantibody to p62/IMP2 coincides with the detection of
HCC.

(IK1, IK2, IK3 and IK4) collected from one patient before the diagnosis of HCC had low ANA
titers. When the diagnosis of HCC was made at time point IK5 (arrow), the ANA titer had
increased significantly and persisted at a high titer for 6 months. From this case, we can see that
the autoantibody of p62/IMP2 can be detected in the early stage of cancers, even one year before
the onset of cancers [48]. Therefore, the autoantibody of p62/IMP2 may be an ideal biomarker in
12

the early detection of cancer. In the following study, more sera with serial years from patients
should be collected to evaluate if it is a real biomarker in the early detection.
Studies demonstrated that tumor diameter is related to 5-year survival rates after surgery.
Therefore, early detection of cancer is very important for promoting patients’ survival rates. The
detection of the autoantibody with ELISA is noninvasive and easily acceptable in clinical
settings [60]. Based on this, p62/IMP2 is a valuable potential biomarker in the early diagnosis.

1.6.2 The role of p62/IMP2 in cancer
To support cell proliferation and stem cells survival, Some reports suggested that
p62/IMP2 can promote cell survival because it can bind to a group of mRNAs such as c-myc,
specificity protein 1 (Sp1), and Insulin-like growth factor 1 receptor (IGF1r) [65, 40]. Embryonal
rhabdomyosarcoma (ERMS) growth and survival relies on the HMGA2-p62/IMP2–NRAS
signaling pathway, and myoblast proliferation and myogenesis are also regulated by HMGA2p62/IMP2 [66]. Other reports suggested that p62/IMP2 controls energy production pathways that
are important for preserving cancer stem cells. In glioblastoma, p62/IMP2 regulates oxidative
phosphorylation (OXPHOS) in primary glioblastoma sphere culture (gliomaspheres). Depletion
of p62/IMP2 inhibits high oxygen consumption in gliomaspheres. It has been demonstrated that
p62/IMP2 can bind several mRNAs such as the mRNA of COX7b, which encode mitochondrial
respiratory chain complex subunits and that p62/IMP2 interacts with NADH dehydrogenase
(ubiquinone) iron-sulfur protein 3 (NDUFS3) [67].
To promote cell migration: important cluster targets of p62/IMP2 consist of proteins
(LIMS2, TRIM54, and LAMB2) involved in cell migration, cell adhesion, and cytoskeleton
remodeling. LIMS2 is an LIM domain protein that binds to and partially dissociates the focal
adhesion complexes [68]. TRIM54 is a ring finger protein specifically expressed in skeletal
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muscle. In p62/IMP2 knockdown RMS cells (RD), LIMS2 is found to be upregulated and
TRIM54 is found to be down-regulated for reducing cell migration, which leads to aggregation
of focal adhesion structures [68]. Conversely, it means that p62/IMP2 expression can keep cell
motility. Studies also provide evidence that p62/IMP2 targets LAMB2 mRNA to the actin
cytoskeleton and regulates LAMB2 translation [69]. LAMB2 is a subunit of laminins, major
extracellular glycoproteins in basement membranes. LAMB2 is thought to mediate the
attachment, migration, and organization of cells into tissues during embryonic development by
interacting with other extracellular matrix components. This data suggests that IMP2 can
enhance the process of cell motility. The previous research on p62/IMP2 suggest that
overexpression of p62/IMP2 plays an important role in the progression of cancer.
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Chapter 2: Hypothesis and Aims
2.1 Specific Aim
Breast cancer is a complex and heterogeneous disease. The progression of it depends on
both the alternation of cancer cells themselves and the deregulation of its surrounding
microenvironment. Although our ability to diagnose and treat breast cancer is improving, breast
cancer is still one of the most common human malignancies in women worldwide. Therefore, it
is necessary to identify new proteins that regulate breast cancer as such proteins may be future
targets for possible therapeutic intervention.
IGF2 mRNA-binding Protein 2 (IMP2, also named as IGF2BP2 or p62) belongs to the
IMP family of proteins that consist of three members: IMP1, IMP2, and IMP3. All the members
of this family are oncofetal proteins. They were initially found as a group of IGF2 mRNAbinding Proteins in rhabdomysarcoma cells. Then, other important target mRNAs were
discovered, including c-myc, beta-actin, H19, CD44, MDR1, and RAS. Interestingly, most of the
target mRNAs are related to progression of cancer.
It has been reported that the expression of p62/IMP2 is associated with several tumor
types. Recently, researchers have suggested that p62/IMP2 can control the expression of proteins
related to cell survival, growth, and movement. However, the mechanisms underlying this
phenomenon remain largely elusive. In this proposal, we will focus on p62/IMP2 in breast cancer
and hypothesize that it plays an important role in the progression of breast cancer progression
Thus, the goal of this proposal is to explore the role of p62/IMP2 within the progression of
breast cancer via both in vitro and in vivo studies, as well as identify some novel targets of
p62/IMP2 or its related genes in breast cancer cells. The completion of this proposal will
expand our knowledge of p62/IMP2 function in breast cancer. We will focus on the following
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aims:
Specific aim 1: The relevance of p62/IMP2 to human breast cancer.
In

this

specific

aim,

p62/IMP2

expression

will

be

evaluated

by

immunohistochemistry on human breast cancer tissues. In addition, the
frequency of its autoantibody will be evaluated by ELISA with sera from breast
cancer patients. These studies will determine whether p62/IMP2 is associated
with breast cancer or not.
Specific aim 2: The impact of p62/IMP2 on breast cancer progression.
To evaluate the role of p62/IMP2 in breast cancer, a panel of breast cancer cells
will be screened. Then, we will implement transfection or shRNA approaches to
alter the expression of p62/IMP2. The generated variants will be used to test the
impact of p62/IMP2 on the cell behavior of breast cancer via a series of in vitro
assay, and in vivo mouse model.
Specific aim 3: The mechanism of p62/IMP2 in breast cancer progression
Although several research articles have reported on the target mRNAs for
p62/IMP2, they varied from different cancer cell lines. To identify novel targets
of p62/IMP2, which is specific to breast cancer, we will first use qPCR arrays to
exame those genes (candidates) whose expression are altered following the de
novo expression of p62/IMP2 in breast cancer cells. Next, we will test if
p62/IMP2 binds to mRNAs of the candidates via RNA immunoprecipation
(RIP). The candidates whose mRNAs can be pulled down together with
p62/IMP2 by RIP are targets, and other candidates are related genes of
p62/IMP2.
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2.2 Significance
Breast cancer can be categorized into several different subtypes on the basis of different
biomarkers. Well-known breast cancer biomarkers include the estrogen receptor (ER), the
progesterone receptor (PR) and the HER2 gene [70, 71]. However, more biomarkers are needed
to further characterize different types of breast cancer. Since p62/IMP2 is a tumor-associated
antigen, we hypothesize that we will find a significant percentage of clinical breast cancer tissues
that overexpress p62/IMP2. Both immunohistochemistry analysis and ELISA analysis of sera
will evaluate whether p62/IMP2 can be used as a biomarker for breast cancer.
The role of p62/IMP2 in cancer progression is still controversial, in part because of the
lack of preclinical data. In our project, we will perform both in vivo and in vitro studies to
examine the role of p62/IMP2 in breast cancer. The results from our in vitro study will provide
evidence for a better understanding of breast cancer progression at the molecular and cellular
level. Through the identification of p62/IMP2 novel targets in breast cancer cells, a series of
novel genes essential in breast cancer progression may be identified in this way, which will
contribute to our understanding of breast cancer at the molecular level. Results from our in vivo
study will confirm the results from the in vitro study and make our data more solid and reliable.
Also, the results of this proposal may provide targets that can be applied to future anti-metastatic
drug design.
In conclusion, breast cancer still remains the second leading cause of cancer-related death
in women (after lung cancer) [7]. In 2014, an estimated 232,670 new cases of invasive breast
cancer were expected to be diagnosed, along with 62,570 new cases of non-invasive breast
cancer (also known as carcinoma in situ). About 40,000 women were expected to die in 2014
from breast cancer, though there has been a decrease in death rates since 1995. The aim of this
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project is to identify molecular targets for future therapies of breast cancer, which could
ultimately lead to a decrease in breast cancer mortality. We hope that the accomplishments in our
research will broaden our knowledge about breast cancer progression and provide theoretical
basis for diagnosis and therapy.
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Chapter 3: Materials and Methods
3.1. Cell lines and cell culture
Human breast cancer cells (MDA-MB-231, LM2-4, and MCF7) were cultured in
Dulbecco’s Modified Eagle Medium (GIBCO, Life Techologies, Grand Island, NY, USA).
Human breast cancer cell line SKBr3 was maintained in McCoy’s 5A medium (GIBCO, Life
Techologies, Grand Island, NY, USA). The medium was supplemented with 10% fetal bovine
serum (GIBCO, Life Technologies, Grand Island, NY, USA) and 100 units/ml penicillin plus
100 μg/ml streptomycin (Thermo Scientific, Waltham, MA, USA) at 37°C with 10% CO2. Breast
cancer cell lines (MDA-MB-231 and LM2-4) were a kind gift from Dr. Francia (UTEP, El Paso,
TX).

3.2. Transfection
For transfection treatment, breast cancer cells were plated in 6-well plates and transfected
using Lipofectamine2000 (Life Techologies, Grand Island, NY, USA) according to the
manufacturers’ instructions. To obtain stably transfected cell clones, cells with transient
transfection were cultured in dishes with DMEM medium containing 1mg/ml G418 for 3 weeks.
After the formation of cell clones, they were picked up using cloning cylinders (Corning,
Tewksbury, MA, USA) and cultured in 96-well plates for growth. Cell lyses from each clone
were collected for Western Blotting to determine which one are p62/IMP2 positive clones or
p62/IMP2 negative clones.
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3.3. Enzyme-linked immunosorbent assay (ELISA)
Polystyrene 96-well microtiter plates (Thermo scientific, Waltham, MA, USA) were
coated overnight at 4℃ with purified recombinant p62/IMP2 at the final concentration of 0.5
μg/ml in phosphate-buffered saline (PBS). Then plates were blocked with 300µl post-coating
solution for 2 hours. After washing away the post-coating solution, antigen-coated wells were
incubated with 100µl human sera diluted at 1:100 for 2 hours. The antigen-antibody complex
were further bound to HRP-conjugated goat anti-human IgG (Santa Cruz Biotechonolgy, Inc.,
Santa Cruz, CA, USA) and detected by the substrate 2, 2’-azino-bis-3-ethylbenzo-thiazoline-6sulfonic acid (ABTS) (ABTS: Sigma-Aldrich, St. Louis, MO, USA). Optical density (OD) value
at a wavelength of 405nm was monitored and collected for data analysis.

3.4. Immunohistochemistry
Multiple breast cancer tissue microarrays were purchased (US Biomax, Inc. MD, USA),
Inc. There were total 104 paraffin-embedded breast cancer tissues and 14 normal breast tissues
on slides. Briefly, after deparaffinization with xylene and rehydration with ethanol, antigen
retrieval was performed by microwave heating methods. 2-3 drops of avidin block solution were
applied to the slide for blocking endogenous biotin activity. After washing, 200µl p62/IMP2
antibody (ABCAM, Cambridge, MA, USA) with 1:100 dilutions was applied to cover every
slide for incubation overnight at 4 ℃ . Then the slides were incubated with Polyvalent
Biotinylated Link as secondary antibody for 1 hour at room temperature. DAB reagent was used
as detection and then was washed away immediately. At last, the slide was counterstained with
hematoxylin, dehydrated with ethanol and stabilized with xylene and then processed for imaging.
All IHC results were read blindly by two independent researchers and further confirmed by a
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pathologist. A four-level scoring system (-, negative; +, weak expression level; ++, moderate
expression level; +++, high expression level) was used to evaluate the staining intensity as
previous study.

3.5. Cell Immunofluorescence
For cell immunofluorescence, cells were cultured into 8-chamber culture slides. Then
cells on slides were fixed with 4% paraformaldehyde and incubated with 100 µl p62/IMP2
antibody with 1:500 overnight at 4°C. After washing, 100 µl FITC-conjugated goat anti-human
IgG (1:100 dilutions) was used as secondary antibody. After washing again, mounting medium
with DAPI (VECTOR Laboratories, Inc. Burlingame, CA, USA) was applied across the slides
for nucleus staining and covering slides. Confocal fluorescence images were acquired with a
laser scanning microscope (LSM 700; Zeiss, New York, NY).

3.6. Proliferation assay
Cells were seeded on to 96-well plates at 5*103 per well, grown for 1 to 7 days. The
growth of cells was determined by the sulforhodamine (SRB) assay. Briefly, the cells were fixed
with 10% trichloracetic acid (TCA) for 1 hour at 4°C, rinsed five times with water, and air dried.
The cells were then fixed with 0.4% SRB in acetic acid for 15 minutes. After washing, unbound
dye was removed by washing 5 times with 1% acetic acid and plates are air dried. Bound
staining was solubilized with 10Mm Tris Base. The colorimetric reading was carried out in a
microplate autoreader at 515nm.

21

3.7. Wound healing assay
Cells were seeded in 6-well plates and cultured in DMEM medium with 2% FBS. After
growing as a confluent cell monolayer, wound scratch was created by tips on cell monolayer.
Detached cells were washed away. Scratch images of wound were photographed every 6 hours.
The level of cell migration into the wound scratch was quantified as migration area at each time
point with Image J software.

3.8. Cell-extracellular matrix adhesion assay
96-well plates were coated with 10ug/ml fibronectin or 10ug/ml type I collagen, and
incubated overnight at 4°C. After washing, non-specific binding sites were blocked with 1%
BSA in serum-free culture medium. The cells (5*103) were added to the coated 96-well plates
and incubated at 37°C for 1 to 2 hours. Non-adherent cells were removed by washing with
washing buffer (0.5% BSA in serum-free cell culture medium). Attached cells were stained by
crystal violet (5mg/ml in 20% ethanol). After unbound dye was washed away, and bound
staining was solubilized. The optical density was measured at 550 nm.

3.9. RNA isolation and quantitative real-time RT-PCR (qRT-PCR)
Total RNA from breast cancer cells was isolated by AllPrep DNA/RNA/Protein Mini Kit
(QIAGEN, Valencia, CA, USA). RNA integrity was assessed by 0.7% agarose gel
electrophoresis. RNA was reverse transcribed with GoScriptTM Reverse Tanscription System.
To evaluate the relative level of p62/IMP2, and c-Myc, quantitative real-time PCR was
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performed with MyiQ Single Color Real-time PCR Detection System. RT Profiler PCR Array kit
was also performed in the same way.
3.10. RNA immunoprecipation
P62/IMP2-bound RIP was performed according to the RiboCluster Profiler RIP-Assay
Kit (Medical & Biological Laboratories CO., LTD. Japan). Briefly, cell lysate was collected
from p62/IMP2 positive cells, and then the whole complexes of p62/IMP-targets from cell lysate
were pulled down with p62/IMP2 antibody. The target mRNAs were separated and isolated by
solution from RIP-Assay Kit for the reverse transcription.

3.11. mRNA half-life analysis
p62/IMP2 positive cells and control cells (106) were seeded in to 6-well plates. After
treated with 5ug/ml actinomycin D (Sigma), these cells were collected after every 30 minutes or
every 2 hours. Total RNA were isolated and from cells collected from different time points. The
amount of GAPDH, c-myc and CTGF mRNAs was quantified by Real-Time RT-PCR.

3.12. Cell proliferation assay
Cells were seeded to 96-well plates at 5*103 per well, grown for 1 to 7 days. The growth
of cells was determined by the sulforhodamine (SRB) assay. Briefly, the cells were fixed with
10% trichloracetic acid (TCA) for 1 hour at 4°C, rinsed five times with water, and air dried. The
cells were then fixed with 0.4% SRB in acetic acid for 15 minutes. After washing, unbound dye
was removed by washing 5 times with 1% acetic acid and plates are air dried. Bound staining
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was solubilized with 10Mm Tris Base. The colorimetric reading was carried out in a microplate
autoreader at 515nm.

3.13. Western blotting analysis
Protein from cell lysates were separated on 10% SDS-PAGE gels and wet transferred to
nitrocellulose membrane (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and then blocked
for 1 hour at room temperature by 5% dry milk in TBS-T buffer (50 mmol/L Tris-HCl, 150
mmol/L NaCl, 0.1% Tween 20). Membranes were then incubated overnight at 4°C or 1 hour at
room temperature with the respective primary antibodies: anti-p62/IMP2 (1:1000), anti-c-myc
(1:1000), and anti-actin (1:1,000), (Santa Cruz Biotechonolgy, Inc., Santa Cruz, CA, USA). Then
Anti-mouse or anti-rabbit secondary antibodies conjugated to horseradish peroxidase (Santa Cruz
Biotechonolgy, Inc., Santa Cruz, CA, USA) were used. X-ray films were developed and results
were visualized.
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Chapter 4: p62/IMP2 is highly associated with human breast cancer
4.1 Overview
A family of recently indentified IGF 2 mRNAs binding proteins (IMP1, IMP2, and IMP3) is
of particular interest in relation to tumorigenesis. This project focuses on one specific IMP
family member, p62/IMP2. This proposal is organized into three parts to explore its role in breast
cancer progression. The first part deals with the association between p62/IMP2 and breast
cancer. The second part is the evaluation of the role of p62/IMP2 in breast cancer progression,
and the third one focuses on the function of p62/IMP2. In this way, the clarification and
validation of its role will allow for a better understanding of the molecular mechanisms of breast
cancer and also provide possible targets for treatment. In chapter 4, we will focus on determining
the association between p62/IMP2 and breast cancer.
4.2 Rationale, experimental design and alternative approach
Specific aim 1: The relevance of p62/IMP2 to human breast cancer progression.
4.2.1 Rationale:
p62/IMP2 is considered to be involved in cancer because it is originally defined as a tumorassociated antigen as well as an oncofetal protein [30, 28]. A high frequency of autoantibody to
p62/IMP2 can be observed in cancer patients’ sera, and overexpression of it has been described
in several tumors in recent reports, including liposarcomas [52], hepatocellular carcinomas [72],
and endometrial adenocarcinomas [73]. Also, p62/IMP2 was reported to be expressed in some
tumor cell lines (HepG2, SNU449, H1299, U-2OS, HT-29, PANC-1, and 1F6) [31]. However,
there is limited research on the expression of p62/IMP2 in breast cancer, which contrasts with the
extensive research on its homolog IMP1 [43, 44]. As a result we are interested in the relationship
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between p62/IMP2 and breast cancer. The goal of specific aim 1 is to evaluate the expression of
p62/IMP2 in human breast cancer tissues and the prevalence of its autoantibody in sera from
breast cancer.

4.2.2 Experimental Design & Methods:
1) Analysis of p62/IMP2 expression in breast tumor tissues: we performed
immunohistochemistry (IHC) to analyze p62/IMP2 expression in tumor tissues by using multiple
breast tissue microarrays (which can provide a high throughput analysis of hundreds of tissue
samples) so we can get a more accurate result. These tissue microarrays contained paraffinembedded tissue specimens collected from patients and labeled with different grades ranging
fromⅠ-Ⅲ, metastasis or non-metastasis, and adjacent non-tumor tissues. Tissue microarrays
were stained with antibody against p62/IMP2. The results from the IHC were analyzed by
comparing normal and tumor tissues, non-metastatic and metastatic tissues, and tissues
corresponding to different tumor stages.
2) Analysis of autoantibody of p62/IMP2 in sera from patients with breast cancer: ELISA
was used to screen a group of sera from patients with breast cancer. Human sera included in the
present study were obtained from the serum bank at the Cancer Autoimmunity and
Epidemiology Research Laboratory at UTEP (University of Texas at El Paso). None of patients
with breast cancer received treatment with any chemotherapy or radiotherapy. Sera were from
normal individuals who had no obvious evidence of malignancy during annual health
examinations. Recombinant p62/IMP2 protein was purified and coated in 96-well plates as
described before.
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4.2.3 Statistical approach:
Tissue microarrays that stained with p62/IMP2 antibody were scored as: 0(-) = no staining,
1(+) = low staining, 2(++) =moderate staining, 3(+++) = strong staining. Protein expression
between tumor tissues and normal tissues was determined by using the Chi-square test (*:
P<0.01, compared with normal group). The mean OD value of the group of patients’ sera was
compared using the Mann-Whitney U test. The frequency of antibody against P62/IMP2 in the
group of patient sera was analyzed using the χ² test with Yate’s correction.

4.2.4 Potential problems & alternative approaches:
We expect that the expression of p62/IMP2 is related to breast cancer and is highly
expressed in advanced stages of breast cancer. Immunohistochemistry is regaded as a wellestablished method of evaluating protein expression. However, it depends on the use of an
antibody with high specificity and sensitivity. Although we have developed an p62/IMP2specific antibody in our lab and commercial antibodies of p62/IMP2 are available now, some
false negative and positive results cannot be avoided entirely. One solution for this problem is to
analyze substantial amount of samples to get correct clinical results. Another alternatie approach
is to detect expression of p62/IMP2 via TissueScan Cancer Q-PCR analysis.
4.3 Results

4.3.1 p62/IMP2 is highly associated with breast cancer
To test the p62/IMP2 overexpression in breast cancer, we performed immunohistochemistry
analysis of p62/IMP2 protein expression in human breast tissues using tissue microarrays. A total
of 118 breast tissue cores were analyzed on slides, which contained 104 tumor tissue sections
and 14 adjacent normal tissue sections. The data we obtained was summarized in Table 3, which
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showed that a high expression of p62/IMP2 (69% 72/104) was seen in human breast tumor
tissues and that a low expression of p62/IMP2 (2/14, corresponding to 14% cases) was seen in
the adjacent normal tissues. We also tried to determine whether there was a correlation between
p62/IMP2 expression and the different stages of breast cancer. However, our data did not support
this notion (Table 4). Figure 4 showed 4 representative examples of the range of p62/IMP2
staining that were analyzed in this tissuearray study using a 4-level scoring system.
p62/IMP2 is also viewed as a tumor-associated antigen. The high frequency of
autoantibodies to p62/IMP2 in sera from cancer patients strongly suggests that this protein is
linked to cancer progression. To detect the prevalence of autoantibody against p62/IMP2 in
human breast cancer, recombinant p62/IMP2 protein was used as coating antigen in ELISA to
screen patients’ sera with breast cancer and benign tumor, and sera from normal individuals. As
shown in Table 5, analysis of sera from 216 patients with breast cancer (including sera from
German, Chinese and Mexican patients) showed that the positive frequency of detectable
autoantibody to p62/IMP2 was 29% (63/216). This was significantly higher than that observed in
the sera from normal individuals and from patients with benign tumors (1%, 0%). From the
distribution of optical density (OD) value of the three groups (Fig.5.), it was evident that most
sera from patients with breast cancer were above the cutoff value (0.32), indicating that these
sera were positive for p62/IMP2 autoantibody. In contrast, only one serum (OD: 0.54) from
normal individuals was above the cutoff value, and no sera from patients with benign breast
tumors was above the cutoff value.
This clinical data showed that the p62/IMP2 was over-expressed in breast cancer and the
overexpressed p62/IMP2 in breast cancer can stimulate the immune system to produce its
autoantibody. Therefore we can conclude that p62/IMP2 is highly associated with breast cancer.

28

Table 3: p62/IMP2 immunohistochemistry on normal and malignant human breast tissue
Positive staining
Type of Tissues
+++

++

+

total

Tumor Tissues(104)

10 (14%)

23 (32%)

39 (54%)

72/104 (69%) *

Normal Tissues (14)

0 (0%)

1 (7%)

1 (7%)

2/14 (14%)

Tissue microarrays stained with p62/IMP2 antibody were scored as: (-) = no staining, (+) = low
staining, (++) =moderate staining, (+++) = strong staining. Protein between tumor tissues and
normal tissues was determined using the Fisher’s exact test. (*: P<0.01, compared with normal
group)
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Table 4: Immunohistochemical analysis of human breast tumors with stages using anti-p62/IMP2 antibody
Positive
Score

+++

++

staining
+

total

Stage Ⅰ(7)

2(29%)

0(%)

3(43%)

5/7(71%)

Stage Ⅱ(49)

4(8%)

13(27%)

16(33%)

33/49(67%)

Stage Ⅲ (7)

2(29%)

4(57%)

1(14%)

7/7(100%)

Stage Ⅳ (1)

0

0

1

1/1(100%)

Scoring Criteria: Tissue microarray stained with antibody against p62/IMP2 were scored as: 0(-)
= no staining, 1(+) = low staining, 2(++) =moderate staining, 3(+++) = strong staining.
Stage Ⅰ or well-differentiated: Cells appear normal and are not growing rapidly.
Stage Ⅱ or moderately-differentiated: Cells appear slightly different than normal.
Stage Ⅲ or poorly differentiated: Cells appear abnormal and tend to grow and spread more
aggressively.
Stage Ⅳ or undifferentiated: (for certain tumors), features are not significantly distinguishing to
make it look any different from undifferentiated cancers which occur in other organs.
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Table 5: Frequency of autoantibody responses to p62/IMP2 protein
Group

Total

Positive (%)

Breast cancer

216

63 (29%)*#

Benign

34

0 (0%)

Normal

73

1 (1%)

Total

323

64

Cutoff value: Mean+3SD of normal group
Breast cancer group vs Normal group: * p<0.01
Breast cancer group vs Benign group: # p<0.01
Breast cancer: sera from patients with breast cancer
Benign: sera from patients with benign tumor in breast
Normal: sera from normal individuals
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Figure 4: Representative examples of staining of p62/IMP2 in breast tumor tissues. Four
representative examples of immunohistochemical staining of p62/IMP2 in breast tumor tissues
were shown here: strong positive staining (example 1), moderate positive staining (example 2),
weak positive staining (example 3), and negative staining (example 4).
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Figure 5: Distribution of autoantibody to p62/IMP2. Titers of autoantibody against p62/IMP2
in sera with breast cancer, sera with benign tumor, and normal human sera. The distribution of
antibody titers is indicated as optical density (OD) obtained from ELISA. The mean + 3SD of
normal human sera were shown in relationship to all sera samples. Titer of anti-p62/IMP2 in sera
of patients with breast cancer was much higher than that observed in sera from patients with
benign tumor and sera from normal individuals. Breast cancer: antibody titer to breast cancer
patients. Benign: antibody titer to breast benign tumor. Normal: antibody titer to normal human
sera.
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Chapter 5: The effect of P62/IMP2 on breast cancer progression
5.1 Overview
Based on the discussion in chapter 4, we have known that p62/IMP2 is highly associated
with breast cancer from chapter 4. The next question then becomes: what is the cancer biology of
p62/IMP2? Is p62/IMP2 just a passer-by induced by other genes or is p62/IMP2 a driver in
breast cancer? This functional study can help us to understand the role of p62/IMP2 in breast
cancer better. The cancer cell behavior is altered significantly when compared with the behavior
of normal cells, such as the manner of cell survival, cell growth, cell migration, and cell
adhesion. In chapter 5, we are aiming to explore the effect of p62/IMP2 on breast cancer
progression via an in vitro study as well as in vivo study. The results from this chapter will
clarify what kinds of cell behavior are affected by p62/IMP2.
5.2 Rationale, experimental design and alternative approach
Specific aim 2: To determine the effect of p62/IMP2 on breast cancer progression
5.2.1 Rationale:
The encoded proteins of target mRNAs of p62/IMP2 contain oncoproteins, receptors,
kinases, receptors, and transcriptional factors which have implications in all aspects of cancer
progression. p62/IMP2 can keep cancer cell survival and growth by binding to a group of
mRNAs, including c-myc, Sp1, and IGF1r. Also, p62/IMP2 has been reported to promote cell
migration, cell polarization, and cytoskeleton remodeling by targeting a group of adhesive
molecules (CAM1, LIMS2, TRIM54, and LAMB2). Additionally, p62/IMP2 supports cancer
stem cells survival and self-renewal by binding to and transporting the transcripts encoded by
nuclear DNA to vicinity of mitochondria for translation. In this chapter, we discuss how we
tested to see if p62/IMP2 can drive breast cancer progression and investigated what kind of role
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p62/IMP2 plays in driving breast cancer with an in vitro study and in vivo study.

5.2.2 Experimental Design & Methods:
We screened a panel of breast cancer cell lines to detect the expression of p62/IMP2 in
breast cancer cells, and then identified some p62/IMP2 positive cell lines and p62/IMP2 negative
cell lines. Our strategy was to use transfection or siRNA to alternate p62/IMP2 expression in
breast cancer cells (knockdown and overexpression) to study the effect of p62/IMP2 on breast
cancer.
After getting transfected variants, we performed a series of in-vitro assays: cell
proliferation assay, wound healing assay, and cell-matrix adhesion assay. 1) Proliferation assay:
cell proliferation can be monitored via numerous methods. Here we used the sulforhodamine B
(SRB) method to detect cell proliferation between the generated variants. Compared with the
MTT method, which is also a common way to detect cell proliferation, the results from the SRB
method are more accurate, stable and reproducible. 2) Wound healing experiment: cells were
cultured in 6-well plates to confluence as a monolayer. Lines (wounds) in the middle area of
wells were scratched and these wounds were photographed at each different time point.
Migration areas were measured with the image-plus software to determine which kind of cells
migrates faster and make the wound heal faster. 3) cell-matrix adhesion assay: this assay was
used to detect the adhesive ability between cancer cells to the extracellular matrix. Two ECM
components (fibronectin and collagen) were coated on 96-well plates respectively. Cells were
seeded into coated-wells and incubated for 1 (collagen) or 3 (fibronectin) hours. After washing
and staining, the adhesive ability of transfected cells was analyzed by calculating cells attached
at the bottom of wells.
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5.2.3 Statistical approach:
Three independent experiments were performed. Results were expressed as the mean ±
standard error of the mean (SEM). The significance of changes between experimental and
control groups were assessed via one-way ANOVA. A p<0.05 was considered statistically
significant.

5.2.4 Potential problems & alternative approaches:
We expected that we can get some p62/IMP2 positive cell lines and p62/IMP2 negative
cell lines for the overexpression and knockdown. We also expected that our data from the in
vitro study would indicate that p62/IMP2 promotes breast cancer progression. One potential
problem was that p62/IMP2 expression may not be found in the cell lines we screened. In this
situation, we believed that the data from tissue microarray and sera of patients should be more
reliable because these data comes directly from patients. Cell lines derived from tumors are
considered as a good model for lab research. However, there is widespread belief that the growth
characteristics as well as the genome background of cells will change in the process of
establishing cell lines or after subsequent passage. There are hundreds of breast cancer cell lines
established in the world, so we ensured to take more cell lines for the screening. If most of cell
lines screened were p62/IMP2 negative, we planned to use overexpression-based transfection for
the further functional study. On the other hand, we planned to use knockdown-based transfection
for the further functional study. The other potential problem was that different cancer cell lines
would have different genetic backgrounds. Therefore working with just one cell line could not
demonstrate the real role of p62/IMP2 in breast cancer progression. We planned to work with
two or more cell lines by implementing the gain-of-function assay and the loss-of-function assay.
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5.3 Results

5.3.1 p62/IMP2 expression in breast cancer cells and Generation of MDA-MB-231 variants,
LM2-4 variants, and MCF7 variants with stable overexpression of p62/IMP2
To test the endogenous expression of p62/IMP2 in breast cancer cells, we screened a
panel of breast cancer cell lines. Western Blotting results of these 8 different cancer cell lines
(SKBr-3, BT474, MCF7, T47D, ZR-75-1, MDA-MB-231, H2N-231, and LM2-4) revealed that
the expression of p62/IMP2 was present in the SKBr-3 cell line but not other cell lines (Fig.6.).
To investigate the biological role of p62/IMP2 in breast cancer progression, three p62/IMP2
negative cell lines (MDA-MB-231, LM2-4 and MCF7) were transfected with pcDNA3.1-p62
vector and empty vector as control. 1mg/ml G418 was added into the transfected cells to ensure a
generation of stable variants expressing of p62/IMP2. The LM2-4 cell line holds higher
metastasis potential than MDA-MB-231 cell line, and MCF7 is a cell line with lower metastasis
potential compared with MDA-MB-231 cell line. Also, LM2-4 cells and MDA-MB-231 cells
share a similar genetic background, which are very different from the genetic background of
MCF7 cell line. It is interesting to consider if we can get the same results with the three different
cell lines. In this way, the role of p62/IMP2 in regards to breast cancer progression can be tested.
More than 30 positive clones were obtained from the three cell lines. Next, two positive clones
(one with high expression of p62/IMP2 and the other with moderate expression of p62/IMP2)
and one negative clone were selected from the MDA-MB-231, LM2-4 and MCF7 cell lines
respectively (Fig.7.). Transfected cells were further confirmed with cell immunoflurosence. The
localization of p62/IMP2 was shown in cytoplasm of positive clones (Fig.8.).
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Figure 6: Analysis of p62/IMP2 expression in a panel of human breast cancer cell lines. The
panel included 8 different kinds of cell lines. p62/IMP2 was detected to be expressed in the
SKBr3 cell line. Cells were harvested and western blotting was performed on the cells lysates
using antibodies against p62/IMP2, and beta-actin.
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Figure 7: Generated variants with overexpression of p62/IMP2 in breast cancer cell lines.
a) Stable transfection of p62/IMP2 into MDA-MB-231 cells. Clone 6 and Clone 8 were
p62/IMP2 positive clones. Clone 5 was a p62/IMP2 negative clone. b) Stable transfection of
p62/IMP2 into LM2-4 cells. Clone 9 and Clone 16 were p62/IMP2 positive clones. Clone 11 was
a p62/IMP2 negative clone. c) Stable transfection of p62/IMP2 into MCF7 cells. Clone 43 and
Clone 9 were p62/IMP2 positive clones. Clone 6 was a negative clone. Cells were transfected
with IMP2/p62-pcDNA3.1 plasmid. MDA-MB-231 cells or LM2-4 cells or MCF7 cells with
empty vector were served as corresponding controls.
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Fig.8.

Figure 8: Cell immunofluorescence staining of p62/IMP2 in transfected cells. There is no
p62/IMP2 staining in these negative clones and in the three parental cell lines. In these positive
clones, the staining of p62/IMP2 is mainly localized to the cytoplasm. Indicated cells were
immunostained with a specific anti-p62/IMP2 antibody, and with DAPI.
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5.3.2 Overexpression of p62/IMP2 promotes cell migration and reduces cell-extracellular
adhesion.
Metastatic tumors are usually correlated with increased cell migration and deregulation
of cell adhesion. Thus, the wound healing assay and the adhesion assay were carried out to
determine the migratory and adhesive characters between p62/IMP2 positive and negative
cells. Our wound healing assay demonstrated that the ‘wound’ was healed faster by p62/IMP2
positive cells than by negative cells (Fig.9.). Stable overexpression of p62/IMP2 increased
wound closure by 50% to 70% (Fig.10.). The result was consistent with other findings, which
indicated that p62/IMP2 can induce a strong cell migration.
Three step hypotheses for tumor cells interacted with ECM were proposed: 1) adhesion
of cell to the ECM, 2) degradation of the ECM by cellular proteases, and 3) migration/invasion
through ECM. Some reports showed that reduced adhesion is necessary for the increase of cell
mobility and in favor of cell spread to distant sites. In contrast, other reports showed that
increased adhesion to the components of ECM can enhance communication between them and
promote cancer cell invasion to the matrigel. Our adhesion study was used to detect the
adhesive ability between cells and a defined matrix. Two components of matrix were coated
into 96-well plates: collagen and fibronectin. We found that overexpressed p62/IMP2 reduced
30%-50% of cell adhesion to extracellular matrix (Fig.12.). Figure 11 demonstrated that
p62/IMP2 positive cells attached to a less extent to the wells, compared to control cells.
Taken together, our data indicated that p62/IMP2 increased cell migration and reduced
cell adhesion. In this way, p62/IMP2 may promote breast cancer cells to spread and migrate to
distant organs of the body. This suggested that overexpression of p62/IMP2 may contribute to
the metastatic behavior of breast cancer cells.
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Figure 9: The wound healing images in p62/IMP2 positive and negative cells.
Overexpression of p62/IMP2 promoted the migration ability of MDA-MB-231 cells, LM2 cells
and MCF7 cells. Wound scratches in different time points allowed for pictures of p62/IMP2 in
MDA-MB-231 cells (a), LM2 cells (b) and MCF7 cells (c). After 24 hours, the wound in
p62/IMP2 positive clones from three cell lines almost healed. In the negative clones, the wound
just become narrower but did not close fully.
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Figure 10: Overexpression of p62/IMP2 promotes migration ability of breast cancer cells.
Overexpression of p62/IMP2 promoted the migration ability of MDA-MB-231cells (a), LM2-4
cells (b) and MCF7 cells (c). Wound healing assay showed that there was increased migration
ability in p62/IMP2 positive cells compared to negative cells and parental cells. The level of cell
migration into the wound scratch was quantified as migration area at each time point. A one-way
ANOVA was applied to analyze the results. *, P < 0.05 when compared to control clones; #, P <
0.05 when compared with parental cells. Values represented mean ± SEM of three independent
measurements.
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Figure 11: Staining images of attached cells from p62/IMP2 positive and negative clones in
the three cell lines. Crystal violet staining images of attached cells from three cell lines: MDAMB-231cells (a), LM2-4 cells (b) and MCF7 cells (c). From the images, we can directly observe
that less p62/IMP2 positive cells were attached at the bottom of wells when compared with the
negative cells and parental cells.
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Figure 12: Overexpression of p62/IMP2 reduces adhesion of cells to extracellular matrix.
The number of attached cells at the bottom of wells was presented as optical density values
following crystal violet staining in the three cell lines: MDA-MB-231 cell line (a), LM2-4 cell
line (b), and MCF7 (c). The results showed that overexpression of p62/IMP2 were able to reduce
adhesion of cells to extracellular matrix when compared to the negative cells and parental cells.
A One-way ANOVA was applied to analyze the results. *, P < 0.05 when compared with
negative clones. Values represent averages ± SE of three independent measurements.
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5.3.3 Overexpression of p62/IMP2 has no effect on cell proliferation
In recent years, it has been reported that p62/IMP2 expression can support cell growth
[40], so we measured cell proliferation ability after overexpression of p62/IMP2 in breast
cancer cells. However, we did not see any effect of p62/IMP2 expression on breast cancer cell
proliferation from the result. The cell growth of variants (p62/IMP2 positive and negative
cells) was tracked for 7 days. As shown in Figure 13, the cell growth curve did not suggest any
statically significant change after the comparison.
Therefore we concluded that p62/IMP2 may be just specifically involved in cell
migration and cell adhesion but not proliferation in the breast cancer progression.
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Figure 13: Cell growth curve of p62/IMP2 variants from three breast cancer cell lines. (a)
Growth curve of the cell proliferation assay in MDA-MB-231 cells. (b) Growth curve of the cell
proliferation assay in LM2-4 cells. (c) Growth curve of the cell proliferation assay in MCF7
cells. There was no obvious effect of p62/IMP2 on the growth of breast cancer cells.
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Chapter 6: Identification of targets of p62/IMP2 or related-genes of p62/IMP2
in breast cancer cells
6.1 Overview
Our data from the in vitro study revealed that p62/IMP2 may promote breast cancer
metastasis by increasing cell migration and reducing cell adhesion. As to cell-matrix adhesion,
some researchers believe that the increase of adhesion can support the talking between cancer
cells and the extracellular environment, which contributes to activation and transmission of
metastasis signaling in cancer cells. Other reports suggested that the reduction of adhesion
promotes cells to spread to other parts of the body. Our conclusion that p62/IMP2 reduces cellmatrix adhesion has interested us on the mechanisms behind it. In this chapter, we explore how
p62/IMP2 regulates breast cancer metastasis by controlling the adhesion of breast cancer cells.
Additionally we also attempt to identify some targets of p62/IMP2 specific to breast cancer
metastasis.
6.2 Rationale, experimental design and alternative approach
Specific aim 3: Identification of targets of p62/IMP2 related with breast cancer metastasis.
6.2.1 Rationale:
Members in IMP family can bind to more than one hundred mRNAs in different cellular
contexts, and which mRNAs can be captured depends on the different cellular context. For
example, the homolog IMP1 binds to IGF2 mRNA in rhabdomyosarcoma cells, but binds to
CD44 in Hela cells. Target mRNAs binding to p62/IMP2 is enhanced in glioblastoma cancer
stem cells with hypoxic conditions. In addition, many targets of IMP are mRNAs of signaling
proteins. IMP1 can bind with MAPK4 mRNA and PTEN mRNA in U2OS cells to regulate
their phospholipid-dependent signaling networks. Here, we will attempt to identify new
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targets of p62/MP2 or p62/IMP2 related genes, and we will try to investigate the specific
function of p62 in signaling pathways. Our approach of identifying novel targets is to mainly
apply for metastasis-related gene profiling analysis because in this way, we can easily and
reliably analyze expression of a focused panel of genes.

6.2.2 Experimental Design & Methods:
Our approach in identifying novel targets was to use metastasis-related gene profiling
analysis (see flow Chart in the right panel: Fig 15). RNA was extracted from p62/IMP2 positive
clones and negative clones, and then total RNA was Figure 14: The flow chart of identifying the novel
candidates of p62/IMP2

reversely transcribed into cDNA. The “Human
Extracellular Matrix & Adhesion Molecules PCR
Array” was used to quantify changes in gene
expression. The Human Extracellular Matrix &
Adhesion Molecules PCR Array contains ECM
proteins

including

basement

membrane

constituents, collagens, and other genes defining
ECM structure. Matrix and other metalloproteinase
that remodel the ECM as well as their inhibitors
were also included. This Matrix & Adhesion array
also represented integrins, selectins, cell-adhesion molecule family members (ICAM, ECAM,
NCAM, PECAM, and VCAM), and other genes which are important to cell adhesion and
cytoskeleton bridging (such as the catenins). qPCR was performed on the MyiQ real-time PCR
detection system (Bio-Rad) with SYBR Green qPCR mastermix (SA Biosciences, Qiagen)
according to the manufacturer’s protocol.
49

Candidate

genes

from

PCR

arrays

were

selected

and validated by RNA

immunoprecipitation (RIP) to see if they were targets of IMP2/p62 or just related genes of
IMP2/p62. RNA immunoprecipitation was briefly performed using a RNA immunoprecipitation
Kit (MBL international). Cells were harvested by adding RIP lysis buffer. Clear supernatant
containing IMP2/p62, IgA beads, and IMP2/p62 antibody, were mixed to perform
immunoprecipitation. After washing and separation, RNAs binding to IMP2/p62 were eluted and
quantified as well as transcripted. PCR with the primers for candidate genes were performed to
examine whether their mRNAs were coimmunoprecipitated.

6.2.3 Statistical approach
Gene profiling analyses was performed a minimum of three times in independent
experiments. The deta deta t was used for data analysis. Fold changes are calculated for each
gene as the difference in gene expression between cells by using the RT Profiler qPCR-array
data analysis software.

6.2.4 Expected outcome and Potential Pitfalls
We expected that we could identify some novel target transcripts of p62/IMP2 in breast
cancer cells. Every RT² Profiler PCR Array profiles the expression of 84 key genes involved in
cell motility or cell adhesion to matrix. However, it does not contain all the related genes. A
complementary method to other PCR Assays should be added, such as The Human Focal
Adhesions RT² Profiler PCR Array.
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6.3 Results

6.3.1 p62/IMP2 can bind to c-myc mRNA in the MDA-MB-231 cells and contribute the
increase of c-myc synthesis.
It is well known that c-myc mRNA is an important target of p62/IMP2. To verify if
p62/IMP2 is able to bind c-myc in breast cancer cells, we pulled down the p62/IMP2-mRNAs
complex via RNA immunoprecipitation. By the RIP and PCR, we found that p62/IMP2 can bind
to c-myc mRNA in our generated MDA-MB-231 cells (Fig.15.). Also both c-myc mRNA
abundance (Fig. 16a and Fig.16b) and c-myc protein amounts (Fig.16c) were found to increase
with overexpression of p62/IMP2 in breast cancer cells, which indicated that this binding can
contribute to the stabilization of c-myc mRNA and the increase of c-myc protein. This data
verified that p62/IMP2 can bind to its targets and does work in breast cancer cells.
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Figure 15: p62/IMP2 can bind c-myc mRNA in MDA-MB-231 cells. After pulling down the
whole p62/IMP2-targets complex (1) and separating target mRNAs from p62/IMP2 protein and
purifying target mRNAs, we got 755ng mRNAs (2) for reverse transcription as a cDNA pool.
Then we used a primer of c-myc to perform the normal PCR and got the band on the gel, which
indicated that c-myc mRNA is a target of p62/IMP2 (3).
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Figure 16: Up-regulation of c-myc by overexpression of p62/IMP2 in MDA-MB-231 cells.
mRNA level of c-myc was analyzed by real-time PCR in MDA-MB-231 cells, and results
showed that c-myc mRNA was increased with the overexpression of p62/IMP2 (a & b). Protein
level of c-myc was analyzed by Western Blotting in MDA-MB-231 cells. The c-myc protein was
also increased with the overexpression of p62/IMP2 (c). So p62/IMP2 can does work in MDAMB-231 cells, and p62/IMP2 can increase c-myc expression in the RNA level as well as in
protein level.
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6.3.2 Changes in human extracellular matrix and adhesion molecular expression in
response to overexpression of p62/IMP2
The local microenvironment of cancer cells plays an important role in cancer progression,
and its major component is the extracellular matrix (ECM). The deregulation of ECM is very
common in cancer, especially in cancer metastasis. Abnormal ECM can promote cancer
metastasis by affecting cell migration and cell adhesion directly. Since our study in specific aim
2 suggested that p62/IMP2 can reduce cell adhesion to promote cancer metastasis, we have an
interest on uncovering the underlying mechanisms, particularly in regards to human breast
cancer. The Human Extracellular Matrix & Adhesion Molecules RT² Profiler PCR Array was
decided to perform with p62/IMP2 positive/negative cells to see which genes work together with
p62/IMP2. This array profiles the expression of 84 genes critical for cell-cell and cell-matrix
interactions, including basement membrane constituents, collagens, and genes defining ECM
structure, metalloproteinases and their inhibitors.
Out of 84 genes, 16 were found to be upregulated with a difference greater than 2 fold
with overexpression of p62/IMP2. Only 2 were found to be down-regulated (Fig.17.). Among
them, the p-value of 7 genes, including 6 up-regulated genes and 1 down-regulated gene, was
less than 0.05 (Table 6). THBS1 was one of the candidates in the array, and its mRNA was
increased 2.4 fold. It is well-known that the turnover of THBS1 mRNA can be increased by cmyc expression. This information validated the result of our qPCR array as reliable. In our
additional qPCR experiment, the increased mRNAs of verscian, CTGF, ADAMTS1, THBS1 and
COL7A1 were confirmed again with our primers in MDA-MB-231 cells (Fig.19a).
In the LM2-4 cells, we also found the increased expression of c-myc with the
overexpression of p62/IMP2 (Fig.18). Therefore we tried to validate the results of qPCR array
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from MDA-MB-231 cells in LM2-4 cells, and CTGF, ADAMTS1, VCAN, and COL7A1 were
confirmed to be increased in mRNA level with overexpression of p62/IMP2 (Fig.19b).
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Figure 17: Volcano plots analysis of adhesion qPCR array. This is a volcano plot that showed
the significant gene expression changes with overexpression of p62/IMP2. Down-regulated
genes are described as green in color, and up-regulated genes are in red. Group 1: clone 6 (p62+)
& Control Group: clone 5 (p62-).
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Table 6: The candidate genes selected from adhesion qPCR array in MDA-MB-231 cells. The expression of 18 genes was shown
to be changed with overexpression of p62/IMP2. 7 genes from them were selected as candidates for the follow-up study (fold
difference: 2; p-value: 0.05).
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Figure 18: Up-regulation of c-myc by overexpression of p62/IMP2 in LM2-4 cells. mRNA
level of c-myc was analyzed by real-time PCR in LM2-4 cells. The c-myc mRNA was increased
with the overexpression of p62/IMP2 (a & b). Protein level of c-myc was analyzed via Western
Blotting in LM2-4 cells. The c-myc protein was also increased with the overexpression of
p62/IMP2 (c).
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Figure 19: The evaluation of candidates from MDA-MB-231 cells and LM2-4 cells.
Increased mRNA of VCAN, CTGF, ADAMTS1, and COL7A1 were confirmed again with our
primers in MDA-MB-231 cells (a). Also in the LM2-4 cells, we validated the results from MDAMB-231 cells in LM2-4 cells, and CTGF, ADAMTS1, VCAN, and COL7A1 were confirmed to
be increased in mRNA level with overexpression of p62/IMP2 (b).
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6.3.3 p62/IMP2 binds CTGF mRNA and stabilizes the transcript
CTGF is well-known to contribute to the process of tissue wound repair. Some functional
features of it are very similar to that of p62/IMP2. CTGF plays important roles in many
biological processes, including cell migration and adhesion, tissue development and stem cell
pluripotency. In addition, it plays significant roles in many human biological disorders like
diabetes, and cancer. It has been known that CTGF expression can be regulated by posttranscriptional regulatory molecules, including microRNAs (miR-18a) in 3’-UTR, which will
result in the repressed translation of CTGF or the degradation of its transcripts. Interestingly, in
previous studies, p62/IMP2 as an mRNA-binding protein can bind its target mRNAs within 5’ or
3’ untranslated regions (UTRs). This information raised the possibility that p62/IMP2 could bind
CTGF mRNAs directly and competitively. Therefore, we mapped that CTGF was a novel target
of p62/IMP2 in breast cancer cells using an RNA immunoprecipitation assay and the experiment
of mRNA half-life detection. The results illustrated in Figure 20a show that CTGF can be pulled
down with p62/IMP2, but not GAPDH. The results in Figure 20c demonstrated that this binding
stabilized the mRNA of CTGF. The well-known target of p62/IMP2, c-myc mRNA is viewed as
a positive control here (Fig. 20a and 20b). Our data indicated that CTGF mRNA is a novel target
of p62/IMP2 in breast cancer cells and that this binding can stabilize mRNA of CTGF.
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Figure 20: CTGF mRNA is a novel target of p62/IMP2. a) In the MDA-MB-231 cell line,
p62/IMP2 bound to mRNA of CTGF and c-myc but not GAPDH. b) p62/IMP2 regulated the
stability of c-myc mRNA in MDA-MB-231 cells. In the negative clone 5, the half-life of c-myc
mRNA is about 30 minutes, but in the positive clone 6, it is about 50 minutes. c) p62/IMP2
regulated stability of CTGF mRNA. The half-life of CTGF mRNA is about 2 hours in negative
clone 5, but it is about 4 hours in the positive clone 6.
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Chapter 7: Discussion and Future Direction

7.1 Discussion

One of our main finding in the present study is that p62/IMP2 expression is highly
associated with breast cancer development. Our data illustrates the expression of p62/IMP2 in
breast cancer tissues using the IHC microarray analysis, and the detection of anti-p62/IMP2
autoantibody in sera from patients with breast cancer as measured by ELISA. Our IHC analysis
found high levels of p62/IMP2 expression in breast cancer tissues when compared to adjacent
normal tissues. The ELISA data showed a high frequency of anti-p62/IMP2 autoantibody in sera
from patients with breast cancer compared to it in the sera from healthy individuals and patients
with breast benign tumor. The overexpression of p62/IMP2 and the detection of p62/IMP2
autoantibodies have been reported to occur in several types of cancers. p62/IMP2 is
developmentally regulated and is expressed in fetal tissues but not in adult livers, and aberrantly
expressed in some hepatocellular carcinomas. Detectable autoantibody to p62/IMP2 was found
to be present in 21.1% of HCC patients from China but not in patients with precursor conditions
such as chronic hepatitis and liver cirrhosis. In 2013, Liu et al. studied the expression of
p62/IMP2 in colon cancer tissues by IHC. Of 64 colon cancer tissue specimens examined, 48
tissues (75.0%, 48/64) expressed p62/IMP2, while normal colon tissues did not show any
expression (0% 0/34) [64]. In a study of 82 patients with digestive canal tumors , 38.6% of
patients had sera that tested positive for autoantibodies to p62/IMP2, and 33.7% of them had
metastatic disease, which suggests that high levels of autoantibody to p62/IMP2 might correlate
with metastasis [62]. Detectable antibody to p62/IMP2 has also been found in other types of
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cancers, such as ovarian cancer and esophageal cancer [61]. Our results reveal that p62/IMP2 is
overexpressed in breast cancer (69.0%) and that the frequency of detectable autoantibody to
p62/IMP2 (29.0%) in the sera of breast cancer patients was significantly higher than the
frequency in sera from normal individuals (1.0%). Several studies have demonstrated that
autoantibody in sera from patients with cancers is produced by the immune system which is
stimulated by some cellular proteins. These cellular proteins were generally called tumorassociated antigens (TAAs), of which may originate via mutated proteins or abnormally
expressed proteins in cancer. The anti-TAA autoantibody and its potential applications in cancer
have been extensively investigated. Autoantibody is stable and can be detected by using ELISA
which is noninvasive, easily acceptable way in clinical. More importantly, the significant
elevation of autoantibody levels also correlates with the occurrence of some cancers so the
detection of the autoantibody can be used for diagnosing early stages of some cancer types. In
future studies, serial serum samples (the collection of sera from an individual every year for
several years before and after the diagnosis of breast cancer) should be examined to see if an
autoantibody to p62/IMP2 can be viewed as a real biomarker in the early diagnosis of breast
cancer.
The functional studies of p62/IMP2 showed that this protein can promote cancer
progression [67, 66, 40]. However, there is not much research that discusses the effect of
p62/IMP2 on breast cancer progression, so it would be interesting to test whether p62/IMP2
expression promotes progression of breast cancer in vitro. To explore the role of p62/IMP2 in
breast cancer in vitro, the growth ability, the migration ability, and the ability to adhere to the
extracellular matrix of cells with overexpressing p62/IMP2 were examined in this study. Our
data demonstrated that p62/IMP2 can increase cell migration and reduce cell adhesion to the
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extracellular matrix, but it has no obvious impact on cell proliferation. Increased cell migration is
important consequence of EMT [74, 75]. To study cell migration we used a scratch woundhealing assay. It is generally believed that EMT is an important event in cancer metastasis. EMT
is also a physiological process that occurs during embryonic development and wound
healing[76]. During wound healing, cells undergo a transient EMT in order to migrate into the
wound site and close the gaps in the epithelial cell sheets that were created by the wounding
process. Also our result of adhesion assay suggested that the reduced adhesion of breast cells
with overexpressed p62/IMP2 to extracellular matrix may promote breast cancer cells to leave
the primary site and spread to distant organs of the body.
In a recent study of breast cancer, Gui et al found that adhesion of primary breast cancer
cells from node-positive women to each of fibronectin and collagen was significantly less than
that in node-negative patients[77]. Many proteins play important roles in this process. Some
proteins such as SOX2 (a regulator of embryonic stem cells) and CO-029 (also a tumorassociated antigen), can increase the migratory and metastatic potentials and decrease adhesion
ability of serous ovarian carcinoma cells [78, 79]. Many proteins like them can contribute to the
disorganization of ECM responsible for the changed adhesion between cells and ECM. In fact,
the process of EMT and disorganization of ECM are independent of each other sometimes, while
in most cases the deregulated ECM can promote EMT and verse versa. Other reports stated that
ECM can modulate EMT to promote cancer metastasis [80]. ECM surrounding tumor cells is
responsible for activating and adjusting intracellular signaling to drive EMT [81]. In short, our
data from in vitro study indicated that p62/IMP2 may be an important regulator in breast cancer
metastasis by increasing the migration ability of breast cancer cells and reducing the adhesion
ability of breast cancer cells to extracellular matrix.
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To further explore how p62/IMP2 regulates wound healing and adhesion, a Human
Extracellular Matrix & Adhesion Molecules RT² Profiler PCR Array was carried out to observe
mRNA changes regulated by p62/IMP2. We found that most of changed genes are upregulated
(such as CTGF, VCAN, ADAMTS1, and COL7A1) by overexpression of p62/IMP2. How
p62/IMP2 regulates these genes has yet not to be reported. Since p62/IMP2 is an mRNA binding
protein, the main function of p62/IMP2 is to stabilize its target mRNAs and upregulate their
expression. Therefore, one possibility is that the mRNAs of upregulated genes with
overexpression of p62/IMP2 in breast cancer cells are bound to p62/IMP2 proteins. Among
them, CTGF was chosen to test such a possibility because the half-life of its mRNA is short. In
our experiment, CTGF mRNA is indicated to be a target of p62/IMP2 by the mRNA half-life
assay and RIP assay. Because of the role of CTGF on cell migration process, studies about the
expression of CTGF correlated to cancer metastasis have increased since 2013[82]. It has been
shown that overexpression of CTGF was related with potential metastasis in pancreatic cancer,
lung cancer, gastric cancer, and osteolytic metastasis of breast cancer [83-85]. In 2014, CTGF
was firstly demonstrated to be unregulated in p62/IMP2 transgenic mice and the unregulated
expression of CTGF is TGF-beta-independent[86]. They suggested that IL13 might be involved
in the up-regulation. However, our data showed that p62/IMP2 can bind to mRNAs of CTGF
directly and stabilize its mRNAs.
As to other genes, they may be regulated by p62/IMP2 directly or indirectly. Here we
how the function of cell migration and cell adhesion are important to and relate with cancer
metastasis. ADAMTS1 is necessary for normal growth, and ADAMTS1 null mice were observed
to manifest growth retardation [87]. In cancer, the role of ADAMTS1 is controversial. This
protein is reported to promote tumor growth and metastasis in some cancers while in others its
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expression is down-regulated as a tumor suppressor role. It is proposed that the proteolytic status
of ADAMTS1 and its mutations determines its impact on tumor metastasis[88]. versican is
viewed as an anti-adhesive molecule. A number of recent studies have demonstrated that
versican, a large chondroitin sulfate (CS) proteoglycan, harbors anti-adhesive properties and the
ability to modulate migration in a number of different cell types, including osteosarcoma cells,
smooth muscle cells (SMCs), and various types of tissue fibroblasts [89]. Its anti-adhesive
characteristic plays a critical role in cancer. Purified versican is able to reduce attachment of
prostate cancer cells and melanoma to fibronectin-coated surfaces in vitro[90], so increased
levels of versican in cancer are believed to be associated with progression of cancer to its
metastatic disease. Previous research has established that elevated levels of versican are observed
in most malignancies such as melanomas, Sarcoma, breast, brain, and ovary cancers [91].
In summary, we identified that p62 is highly expressed in breast cancer tissues. The
increased expression of p62/IMP2 can regulate extracellular matrix to increase cell migration and
reduce cell adhesion, leading to possible cancer metastasis. We also identified CTGF mRNA as a
novel target of p62/IMP2 playing an important role in breast cancer cells. The data further
support that p62/IMP2 may also be a target when treating breast cancer metastasis.
7.2 Future Direction

7.2.1 To determine the role of p62/IMP2 in breast cancer metastasis by in vivo study
Our data from in vitro study indicated that p62/IMP2 may be a critical regulator in breast
cancer metastasis. In future studies, we will use an in vivo study to confirm if p62/IMP2 really
increases the metastatic capacity of breast cancer cells. In regards to which in vivo study, we will
use a spontaneous (orthotopic) metastasis assay because this method can enhance the possibility
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of distant metastatic spread, compared with ectopic transplantation [92]. p62/IMP2 positive cells
and control cells are injected into the mammary fat pad of female SCID mice in two groups
respectively (five mice in each group). After inoculation of tumor cells for weeks, the mice will
be dissected and examined to see if there is a metastatic spread in the lungs. The metastatic
nodules in the lungs will be counted in each group. We will also check to see if metastatic
disease will be developed in other viscera. If the result shows that the number of visible
metastatic nodules increased significantly per lung in the experimental mice when compared
with the control mice, it means that p62/IMP2 expression in breast cancer cells can increase the
probability of metastatic colonization in the lungs. We will also measure the average size of
metastatic tumor in the lungs of two groups of mice to see if p62/IMP2 will affect the growth
rate of metastatic tumor. All metastatic tumors will be photographed. The data mentioned above
should be confirmed further by immnohistochemistry staining. All dissected lung tissues will be
paraffin-embedded, sectioned, stained with haematoxylin and eosin (H&E) and anti-p62/IMP2
antibody to make sure if tumor tissues are p62/IMP2 positive.

7.2.2 The detection of CTGF and p62/IMP2 expression in the breast cancer cells and the
staining of CTGF and p62/IMP2 in tumor tissues.
As a newly identified target of p62/IMP2, CTGF is a very import protein which plays an
important role in breast cancer metastasis. In tumors with increased expression of CTGF, tumor
angiogenesis and metastasis can be commonly observed. Bone metastasis of breast cancer cells
can be inhibited by down-regulating CTGF. Metastasis of breast cancer with high level of CTGF
expression was also suppressed by the injected anti-CTGF monoclonal antibodies in vivo.
Therefore, it would be very interesting to know how IMP2/p62 regulates CTFG expression in
human breast cancer. In our future study, we will detect if p62/IMP2 can increase the CTGF
67

expression in our variants by Western Blotting. Immunohistochemistry will be also performed to
see if a higher expression of CTGF existed in human breast cancer tissues and if there are coexpression of p62/IMP2 with CTGF. Other techniques such SiRNA would be used to see if
p62/IMP2 knock-down attenuates expression of CTGF.
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List of abbreviations

IMP

IGF2 mRNA binding protein

EMT

Epithelial-mesenchymal transition

ECM

Extracellular matrix

MMP

Metalloproteinases

TAA

Tumor-associated antigen

RIP

RNA immunoprecipitation

VCAN

Versican

CTGF

Connective tissue growth factor

ADAMTS1

ADAM metallopeptidase with thrombospondin type 1 motif, 1

THBS1

Thrombospondin 1

ITGB4

Integrin, beta 4

SDS-PAGE

Sodium docecyle sulfate-polyacrlamide gel eletrophoresis

HRP

Hrseradish peroxidase

IP

Immunoprecipitation

OD

Optical density

PBS

Phosphate-buffered saline
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